- Home
- PBYI vs SCPH Comparison
PBYI vs SCPH Comparison
Compare PBYI & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SCPH
- Stock Information
- Founded
- PBYI 2010
- SCPH 2013
- Country
- PBYI United States
- SCPH United States
- Employees
- PBYI N/A
- SCPH N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- SCPH Health Care
- Exchange
- PBYI Nasdaq
- SCPH Nasdaq
- Market Cap
- PBYI 154.1M
- SCPH 173.6M
- IPO Year
- PBYI N/A
- SCPH 2017
- Fundamental
- Price
- PBYI $3.14
- SCPH $2.78
- Analyst Decision
- PBYI Strong Buy
- SCPH Strong Buy
- Analyst Count
- PBYI 1
- SCPH 3
- Target Price
- PBYI $7.00
- SCPH $14.00
- AVG Volume (30 Days)
- PBYI 418.2K
- SCPH 637.0K
- Earning Date
- PBYI 05-01-2025
- SCPH 03-19-2025
- Dividend Yield
- PBYI N/A
- SCPH N/A
- EPS Growth
- PBYI 37.78
- SCPH N/A
- EPS
- PBYI 0.62
- SCPH N/A
- Revenue
- PBYI $230,468,000.00
- SCPH $36,332,000.00
- Revenue This Year
- PBYI N/A
- SCPH $134.20
- Revenue Next Year
- PBYI $3.27
- SCPH $99.40
- P/E Ratio
- PBYI $5.06
- SCPH N/A
- Revenue Growth
- PBYI N/A
- SCPH 167.28
- 52 Week Low
- PBYI $2.23
- SCPH $2.72
- 52 Week High
- PBYI $6.06
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- PBYI 45.33
- SCPH 34.45
- Support Level
- PBYI $3.14
- SCPH $2.87
- Resistance Level
- PBYI $3.56
- SCPH $3.08
- Average True Range (ATR)
- PBYI 0.19
- SCPH 0.18
- MACD
- PBYI -0.05
- SCPH -0.00
- Stochastic Oscillator
- PBYI 17.54
- SCPH 11.70
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.